Added to YB: 2026-09-14
Pitch date: 2026-09-11
ALT [bullish]
Altimmune, Inc.
Author Info
No bio for this author
Company Info
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Market Cap
$651.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.69
P/E
-4.61
EV/Sales
11.7K
Sector
Biotechnology
Category
growth
Biotech Conference coverage Day 3 Session 2 - Altimmune, Inc.
ALT (quick overview): Altimmune is transitioning into a late-stage liver-disease company around pemvidutide, with substantial long-term upside if Phase 3 MASH data show meaningful fibrosis improvement while preserving tolerability and lean mass. Encouraging Phase 2 alcohol-use-disorder results and the fully enrolled alcohol-related-liver-disease study add a second opportunity. Management believes roughly $519 million of cash funds operations through the 2029 MASH readout, but advancing multiple indications will require more capital.
Read full article (2 min)